Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)

Study Overview
=================
Brief Summary
-----------------
Drug-drug interaction study of rosuvastatin and AT-527 (R07496998)

Official Title
-----------------
A Phase 1, Open-Label Study to Evaluate the Effect of AT-527 on the Pharmacokinetics of Rosuvastatin in Healthy Adult Subjects

Conditions
-----------------
Healthy Volunteer Study

Intervention / Treatment
-----------------
* Drug: Drug: AT-527 + rosuvastatin
* Drug: AT-527 + rosuvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug Females must have a negative pregnancy test at Screening and prior to dosing Minimum body weight of 50 kg and body mass index (BMI) of 18-29 kg/m2 Willing to comply with the study requirements and to provide written informed consent Exclusion Criteria: Infected with hepatitis B virus, hepatitis C virus, HIV or SARS-CoV-2 Abuse of alcohol or drugs Use of other investigational drugs within 28 days of dosing Concomitant use of prescription medications, or systemic over-the-counter medications Other clinically significant medical conditions or laboratory abnormalities

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AT-527 + rosuvastatin (simultaneous) n=14<br> | Drug: Drug: AT-527 + rosuvastatin<br>* Day 1: A single dose of rosuvastatin will be administered. Day 8: A single dose of AT-527 and rosuvastatin will be co-administered.<br>* Other names: AT-527 is also know as R07496998;|
| Experimental: AT-527 + rosuvastatin (staggered) n=14<br> | Drug: AT-527 + rosuvastatin<br>* Day 1: A single dose of rosuvastatin will be administered. Day 8: A single staggered dose of AT-527 and rosuvastatin will be administered (2 hours later)<br>* Other names: AT-527 is also know as R07496998;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the effect of co-administration of AT-527 on the single-dose pharmacokinetics (PK) of rosuvastatin | Maximum plasma concentration (Cmax) | Day 1, Day 8 | 
| To evaluate the effect of co-administration of AT-527 on the single-dose pharmacokinetics (PK) of rosuvastatin | Area under the concentration-time curve (AUC) | Day 1, Day 8 | 
| To determine the effect of a staggered dose of AT-527 administered 2 hours before rosuvastatin on the PK of rosuvastatin | Area under the concentration-time curve (AUC) | Day 1, Day 8 | 
| To determine the effect of a staggered dose of AT-527 administered 2 hours before rosuvastatin on the PK of rosuvastatin | Maximum plasma concentration (Cmax) | Day 1, Day 8 |